Antibodies
1 August 2014
Initiation of Multiple Ascending Dose Phase 1 Study of PRX002 in Patients With Parkinson’s Disease1 August 2014
FDA Advisory Committee Panel Provides Favorable Recommendation on Baxter’s HyQvia for Primary Immunodeficiency31 July 2014
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission30 July 2014
EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME)29 July 2014
Merck Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma25 July 2014
MacroGenics’ DART Candidate IND for Colorectal Cancer, MGD007, Cleared to Start Enrolling Patients23 July 2014
Ganymed Completes Recruitment for Randomized Phase 2 FAST Trial of IMAB362 for Gastroesophageal Cancer23 July 2014
MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical Development23 July 2014
Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma22 July 2014
FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer16 July 2014
Resolve Initiates Phase 2 Clinical Study in SLENews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports